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OBJECTIVE: We aimed to evaluate the association between platelet (PLT) count and the risk and progression of
hand, foot, and mouth disease (HFMD).
METHODS: In total, 122 HFMD patients and 40 healthy controls were enrolled in the study. The differences
between variables among the different subgroups were compared. Logistic regression analyses were performed
to assess the relationship between various parameters and HFMD risk/progression. Sensitivity analysis was
conducted by detecting the trend of the association between PLT count quartiles and HFMD risk/progression.
A generalized additive model was used to identify the nonlinear relationship between PLT count and HFMD risk/
progression. The relationship between gender and PLT count as well as the risk/progression of HFMD was
detected using a stratified logistic regression model.
RESULTS: Significant differences were observed in terms of age, male/female ratio, white blood cell (WBC)
count, and PLT count between patients with stage I-II, III-IV HFMD and healthy controls. Moreover, the alanine
aminotransferase and magnesium levels between patients with stage I-II and III-IV HFMD significantly differed.
Moreover, a significant difference was noted in the male/female ratio among the different PLT groups. The
group with a low PLT count had a lower risk of HFMD progression than the group with a high PLT count (Q4)
(p=0.039). Lower age, male gender, and WBC count were found to be associated with HFMD risk. Meanwhile,
PLT count was correlated to HFMD progression. The sensitivity analysis yielded a similar result using the
minimally adjusted model (p for trend=0.037), and minimal changes were observed using the crude and fully
adjusted model (p for trend=0.054; 0.090). A significant nonlinear relationship was observed between PLT count
and HFMD progression after adjusting for age, gender, and WBC (p=0.039).
CONCLUSIONS: PLT was independently associated with HFMD progression in a nonlinear manner.
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’ INTRODUCTION
Hand, foot, and mouth disease (HFMD) is a common
syndrome mainly caused by intestinal viruses of the
picornaviridae family (1). HFMD usually affects children
younger than 5 years (2). The most common clinical
symptoms are ulcers and rashes on certain body parts (3).
Most patients with mild HFMD can recover spontaneously.
However, about 1.1% of individuals in China develop severe
HFMD and present with serious clinical complications, such
as encephalitis, aseptic meningitis, and even death, during
progression (4,5). Antiviral therapy and vaccination against
certain enterovirus have been the primary methods used for
treating and preventing HFMD (6,7). However, in severe
cases, patients are resistant to the traditional therapy and had
a poor prognosis. Due to its potential danger, HFMD has
become an important health concern among children world-
wide. Thus, early prevention and therapy of HFMD may
be imperative.
Recently, several studies (8-10) have focused on the risk
factors of severe HFMD. Some pathogens, including enter-
ovirus 71, were found to be responsible for the progression of
HFMD (11). Moreover, inflammation was implicated in the
development of HFMD (12). Meteorological and geographi-
cal factors were closely associated with the incidence of
HFMD (13). However, there are some limitations in the man-
agement of such condition. For example, several labora-
tory parameter tests are not available in primary medicalDOI: 10.6061/clinics/2020/e1619
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institutions. On the other hand, a high number of children
present with herpangina and HFMD in suburban districts
during the epidemic season. Therefore, the identification of
low-cost and easily available alternative biomarkers for
HFMD risk and progression is of great clinical significance.
Platelet (PLT) is an important component of the blood,
and it plays an important role in several physiological and
pathological processes, such as coagulation, thrombosis, and
inflammation (14). PLT count is associated with inflammatory
diseases. Inflammation correlated with endothelial dysfunc-
tion is a cause of organ failure and is associated with PLT
activation and consumption (15). In addition, a relationship
was observed between changes in PLT count and the
prognosis of critically ill patients (16-18). Inflammatory and
thrombotic conditions may cause changes in PLT size (19).
Larger PLTs are more reactive than smaller ones as they can
more easily release chemical mediators in response to various
stimuli. Hence, alterations in PLT count are associated with
morbidity and mortality in patients with various diseases.
Moreover, PLT is easily available as it is a parameter of
complete blood count test, which is performed using the
automatic analyzer. Thus, it can be generalized and applied
in primary medical institutions.
To identify the possible role of PLT in HFMD, we evaluated
the association between PLT and HFMD risk and progression.
HFMD was classified into four clinical stages based on the
involvement of injured organs and disease severity. Mean-
while, the relationship between other clinical/laboratory para-
meters and HFMD as well as the role of other variables on the
association between PLT and HFMD were analyzed.
’ MATERIAL AND METHODS
Patient population
The patients diagnosed with HFMD at First People’s
Hospital of Lianyungang between January 2016 and April
2018 were screened. Nearly 600 patients visit the outpatient
department daily. Patients who were diagnosed with HFMD
at presentation were enrolled in the current study. HFMD
was diagnosed according to the World Health Organization
criteria for HFMD (20). The patients with HFMD were
divided into four groups based on clinical stages: clinical
stage I (no involvement of other organs), stage II (involvement
of the nervous system), stage III (early cardiopulmonary
failure), and stage IV (cardiopulmonary failure). However,
patients with signs and symptoms not consistent with the
diagnostic criteria and those who were immunosuppressed
were excluded. This retrospective study was conducted
according to the Declaration of Helsinki. Moreover, informed
consent was obtained from the guardians of all participants.
Data collection
We obtained data about the clinical and laboratory para-
meters of the patients from the medical records. Demographic
and clinical data, such as age and gender, were reviewed
respectively. Laboratory data included white blood cell (WBC)
count and hemoglobulin (HB), PLT, alanine aminotransferase
(ALT), aspartate aminotransferase (AST), albumin (ALB),
serum creatinine (Scr), calcium (Ca), phosphorus (P), and
magnesium (Mg) levels. All parameters were assessed during
the first day after the admission of the patients to the hospital.
The data of the controls, including age, gender, WBC count,
and PLT count, were obtained. PLT count was also expressed
in quartiles.
Statistical analysis
Continuous variables were expressed as mean/standard
deviation of the normal distribution or median/quartile in
the skewed distribution. Meanwhile, categorical variables
were presented as frequency. One-way analysis of variance
and the Kruskal–Wallis H test were used to detect the
differences in continuous variables. The chi-square test was
utilized to identify the differences in categorical variables.
Logistic regression analyses were used to assess the relation-
ship between various clinical and laboratory parameters and
HFMD risk/progression. The association between PLT count
and HFMD risk/progression was assessed via a logistic reg-
ression analysis using the crude, minimally adjusted, and
fully adjusted models. Moreover, a sensitivity analysis was
performed by detecting the trend of the association between
PLT count quartiles and HFMD risk/progression. A general-
ized additive model was used to identify the nonlinear
relationship between PLT count and HFMD risk/progres-
sion. A subgroup analysis in terms of sex of the patient was
conducted using the stratified logistic regression model.
The likelihood ratio test was used to detect the interac-
tion between the subgroups. Statistical analyses were con-
ducted using the software R and EmpowerStats (http://
www.empowerstats.com, X&Y Solutions, Inc., Boston, MA).
A p value o5% was considered statistically significant.
’ RESULTS
Baseline characteristics of the participants
A total of 122 HFMD patients and 40 controls were
enrolled in our study (Table 1). There were 104 and 18
patients with stage I-II (n=40, stage I; n=64, stage II) and III-
IV HFMD, respectively. The median ages of the patients with
stage I-II HMFD, those with stage III-IV HFMD, and controls
were 1.83, 1.87, and 6, respectively. Significant differences
were observed in terms of age, male/female ratio, WBC
count, and PLT count among patients with stage I-II and III-
IV HFMD and controls. Moreover, the ALT and Mg levels
between patients with stage I-II and those with III-IV HFMD
significantly differed. No statistically significant differences
were observed in terms of age, WBC count, and HB, ALT,
AST, Scr, Ca, P, and Mg levels among the different PLT
groups (Table 2). The male/female ratio significantly differed
among the PLT groups (Table 2). The group with a low PLT
count (Q1) had a lower risk of HFMD progression than the
group with a high PLT count (Q4) (p=0.039) (Table 2).
Univariate logistic regression analysis
The results of the univariate logistic regression analyses
are shown in Table 3. WBC count was positively associated
with HFMD risk (95% CI: 1.035-1.346, p=0.014), indicating
that higher level of WBC count increased the risk of HFMD
susceptibility. Lower age and male gender were also found to
be associated with HFMD risk. However, HB, PLT, ALB,
ALT, AST, Scr, Ca, P, and Mg levels were not associated with
HFMD risk, and a relationship was not observed between
age, male gender, WBC count, and HB, ALB, ALT, AST, Scr,
Ca, and p levels as well as HFMD progression.
Relationship between PLT count and HFMD risk and
progression
We used the univariate logistic regression model to
evaluate the association between PLT count and HFMD.
The non-adjusted and adjusted models are shown in Table 4.
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In the crude model, PLT count was not associated with
HFMD risk. Moreover, similar results were obtained using
the minimally adjusted and fully adjusted models. In the sen-
sitivity analysis, PLT was considered a categorical variable
(quartile), and the same trend was observed. PLT count was
found to be associated with HFMD progression regardless
whether the crude, minimally, and fully adjusted model was
used. Sensitivity analysis yielded a similar result using the
Table 1 - Baseline characteristics of the participants in terms of disease state.
Patients with stage I-II HFMD (n=104) Patients with stage III-IV HFMD (n=18) Controls (n=40) p-value
Age (years) 1.83 (1.31, 2) 1.87 (1.21, 2.75) 6 (4, 8.25) o10-4
Gender (male/female) 76/28 15/3 20/20 0.01
WBC count (109/L) 11.29 (9.43, 14.57) 12.95 (10.71, 17.92) 8.75 (6.95, 10.98) 0.001
HB level (g/L) 119.5 (114, 123) 118 (109, 125) -- 0.86
PLT count (109/L) 261.23±77.02 309.06±74.49 283.75±55.86 0.044
ALT level (u/L) 16 (12, 21) 14.5 (12, 19.5) -- 0.046
AST level (u/L) 31 (26, 41) 27 (25, 38) -- 0.14
ALB level (g/L) 45.6 (43.2, 47.7) 45.75 (43.58, 48.83) -- 0.99
Scr level (umol/L) 21.45 (17.38, 24.9) 20 (17.8, 22.8) -- 0.53
Ca level (mmol/L) 2.48±0.10 2.46±0.13 -- 0.39
P level (mmol/L) 1.76±0.21 1.75±0.22 -- 0.79
Mg level (mmol/L) 0.90±0.09 0.85±0.08 -- 0.024
HFMD: hand, foot, and mouth disease, WBC: white blood cell, HB: hemoglobulin, PLT: platelet, ALT: alanine aminotransferase, AST: aspartate
aminotransferase, ALB: albumin, Scr: serum creatinine, Ca: calcium, P: phosphorus, Mg: magnesium.
Table 2 - Baseline characteristics of the participants in terms of PLT quartiles.
Q1 (40) Q2 (38) Q3 (40) Q4 (40) p-value
Age (years) 2.0 (1.33, 3) 2.5 (1.83, 5.75) 2 (1.33, 4.0) 2 (1.65, 4.0) 0.80
Gender (male/female) 28/12 33/5 20/20 26/14 0.006
WBC count (109/L) 10.41 (9.24, 12.78) 10.77 (8.09, 12.67) 10.32 (8.02, 14.62) 12.2 (10.26, 14.80) 0.27
HB level (g/L) 118.5 (111.75, 123.5) 119.5 (113.5, 125.5) 119 (111, 122) 119 (116, 122.25) 0.78
ALT level (u/L) 14 (11, 21) 16 (13, 20.0) 16 (13, 22.2) 16 (12, 20.2) 0.729
AST level (u/L) 31 (26, 39) 30 (27, 39) 31.5 (25.9, 40.2) 31 (25, 41) 0.923
ALB level (g/L) 43.9 (42.6, 46.1) 45.4 (43.9, 47.3) 46.3 (44.2, 48) 45.7 (43.4, 48.3) 0.133
Scr level (umol/L) 22.4 (16.9, 23.8) 22.8 (19.3, 25.7) 21.1 (16.9, 24.3) 20.5 (17.8, 24.8) 0.621
Ca level (mmol/L) 2.46±0.11 2.46±0.09 2.48±0.12 2.50±0.11 0.419
P level (mmol/L) 1.72±0.20 1.71±0.17 1.79±0.21 1.78±0.23 0.202
Mg level (mmol/L) 0.89±0.10 0.89±0.09 0.91±0.10 0.88±0.09 0.647
HFMD Q4 vs Q1 0.084
None 6 12 11 11
Stage I-II 32 22 24 22
HFMD Q4 vs Q1 0.039
Stage I-II 32 22 24 22
Stage III-IV 2 4 5 7
HFMD: hand, foot, and mouth disease, WBC: white blood cell, HB: hemoglobulin, PLT: platelet, ALT: alanine aminotransferase, AST: aspartate
aminotransferase, ALB: albumin, Scr: serum creatinine, Ca: calcium, P: phosphorus, Mg: magnesium.
Table 3 - Univariate analysis results (HFMD stage I-II versus control; *HFMD III-IV versus HFMD stage I-II).
Index Effect size (b) 95% CI p-value
Age 0.233 *1.234 0.140-0.388 *0.829-1.835 o10-4 *0.299
Gender
Female Reference: 1  
Male 2.714 *1.842 1.274-5.782 *0.495-6.848 0.0096 *0.362
WBC count 1.180 *1.1093 1.035-1.346 *0.995-1.237 0.014 *0.062
HB level  0.001 *0.995 0.001-0.001 *0.943-1.049 0.999 *0.855
PLT count 0.996 *1.008 0.990-1.0008 *1.001-1.015 0.097 *0.020
ALB level 0.999 *0.999 0.00001-1.0001 *0.868-1.149 0.999 *0.985
ALT level 0.001 *0.973 0.001-0.001 *0.914-1.036 0.999 *0.392
AST level  0.001 *0.976 0.001-0.001 *0.933-1.021 0.999 *0.289
Scr level 0.001 *0.978 0.001-0.001 *0.9001-1.062 0.999 *0.597
Ca level  0.001 *0.126 0.001-0.001 *0.0012-13.103 0.999 *0.382
P lebel 0.001 *0.725 0.001-0.001 *0.067-7.842 0.999 *0.791
Mg level  0.001 *0.002 0.001-0.001 *0.00001-0.505 0.998 *0.028
HFMD: hand, foot, and mouth disease, WBC: white blood cell, HB: hemoglobulin, PLT: platelet, ALB: albumin, ALT: alanine aminotransferase,
AST: aspartate aminotransferase, Scr: serum creatinine, Ca: calcium, P: phosphorus, Mg: magnesium.
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minimally adjusted model, and only minimal changes were
observed using the crude and fully adjusted models.
Analyses of nonlinear relationships
With the use of PLT as a continuous variable, the nonlinear
relationship between PLT count and HFMD risk/progression
was assessed. Results showed that PLT count was not
associated with HFMD risk after adjusting for age, gender,
and WBC count based on the nonlinear relationship analysis
(Table 5, Figure 1). Notably, a significant nonlinear relation-
ship was noted between PLT count and HFMD progression
after adjusting for age, gender, and WBC (Table 5, Figure 2).
Results of the subgroup analyses
As shown in Table 6, the relationship between PLT count/
quartiles and gender as well as HFMD risk and progression
was not significant.
’ DISCUSSION
Increasingly attention has been paid to the prevention and
monitoring of HFMD. Outbreaks of HFMD commonly occur
worldwide (21). The identification of a low-cost, easily avai-
lable predictor for HFMD risk and progression is effective for
the prevention of HFMD. This study first investigated the
association between PLT count and the risk and progression
of HFMD. Our investigation showed that a significant, inde-
pendent, and nonlinear relationship existed between PLT
count and HFMD progression. Moreover, PLT can be an
alternative, low-cost biomarker for HFMD progression.
Several mechanisms may account for our findings. First,
platelets promote the transfer of progenitor cells and leu-
kocytes to the inflammation sites and release of several
substances that mediate inflammation (22). Inflammation
plays an important role in the development of HFMD.
Systemic inflammatory response may play a role in the
pathogenesis of HFMD (23). Enterovirus, which causes
HFMD, significantly increases the release of circulating
inflammatory mediators (23). Interleukin (IL)-27 is associated
with early cardiopulmonary failure in enterovirus-induced
HFMD (24). Cytokines and chemokines play a role in the
development of HFMD (25). Moreover, patients with mild
HFMD but without nervous system complications had
increased levels of serum inflammatory cytokines (25). The
abovementioned data support the notion that PLT may
increase the susceptibility to HFMD by promoting inflam-
mation. Studies have shown that platelets contribute to the
risk of sepsis and acute lung injury (26). Moreover, they
play an important role in trans-cellular metabolism, leading
to the production of pro-inflammatory and anti-inflamma-
tory molecules (27). An inflamed endothelium was found to
be associated with leukocytes, which can roll on the template
of adherent platelets and can migrate through the platelets
(28). Second, platelet size can affect these functions. Mean
PLT volume is the most commonly used marker in eva-
luating the changes in platelet function and activation.
Platelets levels increase in high-grade inflammation, result-
ing in the decreased level of mean PLT volume due to the
migration of large reactive platelets to inflammatory sites
and the consumption of these platelets (29). Finally, HFMD is
commonly caused by multiple viruses, including enterovirus
(30), which may affect the PLT count. Severe HFMD is often
complicated by organ damage, which may exacerbate
inflammatory response, and this phenomenon is associated
with platelet activation. Increased PLT count may be an early
warning sign of severe HFMD, thereby indicating that a
more aggressive treatment may be required.
Our findings also give rise to two questions. First, the in-
depth mechanism behind the role of PLT in the development
of HFMD must be further investigated. In addition to
inflammation, other factors may also be involved in the
pathogenesis of HFMD. Second, multiple pathogens can
induce the onset of HFMD. Whether a close relationship
exists between PLT count and the infectious pathogens of
HFMD remains unclear. Previous studies have investigated
the risk factors for HFMD progression. Chen et al. (23) have
shown that IL-6, IL-10, and IL-13 were associated with the
development of HFMD in children. David Lee et al. (13) have
presented that weather conditions and geographic location
play a role in the occurrence of HFMD epidemics. Liu et al.
(31) have revealed that a moderately warm environment
Table 4 - Relationship between PLT and HFMD risk and progression in the different models.
Index Crude model Minimally adjusted model Fully adjusted model
PLT count #0.996 (0.990-1.001), 0.097 #0.993 (0.984-1.003), 0.172 #0.999 (0.998-1.0003), 0.999
*1.008 (1.001-1.015), 0.02 *1.008 (1.002-1.015), 0.016 *1.009 (1.001-1.018), 0.036
PLT quartile
Q1 #Reference #Reference #Reference
*Reference *Reference *Reference
Q2 #0.345 (0.112-1.054), 0.062 #0.672 (0.071-6.347), 0.729 #0.999 (0.00001-1.0004), 0.999
*2.909 (0.489-17.287), 0.240 *2.585 (0.429-15.590), 0.300 *3.021 (0.393-23.213), 0.288
Q3 #0.409 (0.133-1.262), 0.119 #0.247 (0.029-2.094), 0.199 #0.999 (0.00001-1.0003), 0.999
*3.333 (0.595-18.674), 0.171 *4.019 (0.691-23.391), 0.122 *2.728 (0.317-23.456), 0.361
Q4 #0.375 (0.121-1.165), 0.105 #0.237 (0.029-1.956), 0.181 #0.999 (0.00001-1.0005), 0.999
*5.091(0.966-26.844), 0.055 *5.337 (1.002-28.419), 0.049 *6.585 (0.822-52.724), 0.076
P for trend #0.136 #0.122 #0.999
*0.054 *0.037 *0.090
HFMD: hand, foot, and mouth disease, PLT: platelet, crude model: adjusted for none, minimally adjusted model: adjusted for age and gender, fully
adjusted model: adjusted for age, gender, WBC count and HB, ALB, ALT, AST, Scr, Ca, P, and Mg levels; #: relationship between PLT count and HFMD risk,
*: relationship between PLT count and HFMD progression.
Table 5 - Nonlinear association between PLT count and HFMD
risk/progression.
Index Effect size (b) 95% CI p-value
HFMD risk 961.27 19.33-47802.25 0.296
HFMD progression 0.016 0.0016-0.163 0.039
HFMD: hand, foot, and mouth disease, PLT: platelet.
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promotes the transmission of HFMD viruses, whereas par-
ticularly cold and hot climate conditions inhibit their
transmission. Liu et al. (32) have reported that blisters and
constipation are potential warming signs, and front-line
clinicians must manage the sudden increase in the number of
children diagnosed with mild HFMD during a pandemic.
Previous findings indicated that the incidence and progres-
sion of HFMD are associated with environmental factors,
which can affect the risk of inflammation. PLT may affect
HFMD progression by regulating inflammation. Our find-
ings were consistent with the abovementioned data, and
PLT was found to be correlated the severity of HFMD.
Interestingly, PLT was not associated with the risk of stage
I-II HFMD, indicating that PLT was not involved in the
development of early-stage HFMD. Notably, in the epidemic
of HFMD or in susceptible cases, the changes in PLT count
Figure 1 - Nonlinear association between PLT count and HFMD risk.
Figure 2 - Nonlinear association between PLT count and HFMD progression.
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could not reflect the risk of HFMD. Meanwhile, in HFMD
cases, PLT count reflects the severity of HFMD.
This study had several limitations that should be con-
sidered. First, its retrospective study design might have led
to recall bias. However, we obtained comparatively reliable
data. Second, the correlation analysis between PLTcount and
prognosis was not assessed due to the lack of prognostic
data. Finally, the limited number of participants reduced the
statistical power. Hence, studies with a larger sample size
should be conducted in the future.
In conclusion, PLT count was independently associated
with HFMD progression in a nonlinear manner. Thus, it can
be used as an alternative, low-cost biomarker for HFMD
progression.
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